Press release
United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation
Review manuscript available in the journal Physiological Reviews SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nReview manuscript available in the journal Physiological Reviews\n\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews. The manuscript is the first detailed overview of the current state of the xenotransplantation industry and, in one place, collects the vast history of the technology used to generate genetically engineered pigs and the research conducted to date on the xenotransplantation of porcine hearts and kidneys.\n\n\nThe manuscript can be found at Physiological Reviews using the following URL: https://doi.org/10.1152/physrev.00041.2023\n\n\nXenotransplantation is one of four organ manufacturing platforms being developed by United Therapeutics, the goal of which is to provide an unlimited supply of tolerable, transplantable organs to patients with end-stage organ disease.\n\n\n“We’ve seen the collective efforts of scientists over the last several decades lead to meaningful scientific advances, from animal cloning to gene editing, that has allowed the industry to enhance the suitability of porcine organs for human use,” said Leigh Peterson, Ph.D., Executive Vice President, Product Development and Xenotransplantation at United Therapeutics and lead author of the manuscript. “We believe the continued progress by United Therapeutics and our scientific collaborators will lead to the regular use of porcine organs to help patients in need.”\n\n\nThe authors of the manuscript are Leigh Peterson, Ph.D.; Sir Magdi Yacoub, OM, FRS; David Ayares, Ph.D; Kazuhiko Yamada, M.D., Ph.D; Daniel Eisenson, M.D.; Bartley Griffith, M.D., FACS, FRCS; Muhammad Mohiuddin, MBBS; Will Eyestone, Ph.D; J. Craig Venter, Ph.D; Ryszard T. Smolenski, M.D., Ph.D, and Martine Rothblatt, Ph.D.\n\n\nUnited Therapeutics has three xenotransplantation programs in development with the goal to provide hearts and kidneys to patients in need. The UHeart™ is a heart from 10-gene modified pig, the UKidney is a kidney from a 10 gene-modified kidney, and the UThymoKidney™ is a kidney and thymus from a one gene-modified GalSafe™ pig.\n\n\nBeyond xenotransplantation, Uni...